Case Control Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Dec 14, 2016; 22(46): 10210-10218
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10210
Figure 5
Figure 5 The hepatitis B envelope antigen seroconversion proportion after treatment baseline at different levels of hepatitis B surface antigen at week 24 during pegylated interferon α-2a sequential therapy. HBsAg: Hepatitis B surface antigen.